The Pharmacy Times® Pneumococcal Resource Center is a comprehensive resource for clinical news and expert insights for any infection caused by the bacteria Streptococcus pneumoniae, or pneumococcus.
September 10th 2025
The 21-valent pneumococcal conjugate vaccine (PCV21) elicited favorable immunogenicity and safety in infants and toddlers who were coadministered common pediatric vaccines, such as the measles-mumps-rubella vaccine.
Investigational Vaccine Has Non-Inferior Immune Response Compared to PCV20 for Pneumococcal Disease
December 13th 2023Clinical trial results show the immunogenicity, tolerability, and safety of V116 compared to a pneumococcal 20-valent conjugate vaccine for adults who had not previously received a pneumococcal vaccine.
Read More
FDA Approves Pentavalent Vaccine for Most Common Serogroups That Cause Meningococcal Disease
October 20th 2023Penbraya (Pfizer Inc) is the first and only approved pentavalent vaccine that confers protection against the most common meningococcal serogroups—A, B, C, W-135, and Y, in individuals 10 through 25 years of age.
Read More
Nasopharyngeal Swabs Most Sensitive for Pneumococcal Detection in Infants
October 20th 2023Study authors suggest that saliva samples can be a complementary testing method to provide additional information on pneumococcal carriage and serotypes that may be undetected by nasopharyngeal testing.
Read More